Related Pages for AUROPHARMA
- Option Chain
- Straddle OC
- Max Pain
- Put Call Ratio
- Option Analytics
- Call OI vs Put OI
- Strike Flow
- Call OI Chg vs Put OI Chg
- Call Vol vs Put Vol
- Buildup & Unwinding
- Vega Divergence
- Multi Strike OI
- Multi Straddle Analysis
- Price vs OI
- Time Series Table
- Time Series Multi Chart
- Volatility Skew
- Premium Decay
- IV - HV
- IV Intraday
- Future Chain
- Future Intraday Analysis
- Technical
- Financials
- Chart
- About
No results found.
AUROPHARMA
Related News - AUROPHARMA
Aurobindo Pharma: Schedules Meeting With Analysts And Investors On September 24 At 2.30 PM.
21 Sep 2026 04:18 PM
Aurobindo Pharma: Schedules Meeting With Analysts And Investors On September 24 At 2.30 PM.
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-II API Facility Ends with One Procedural Note.
15 Sep 2026 06:18 PM
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-II API Facility Ends with One Procedural Note.
Aurobindo Pharma: Gains USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 MCG And 80 MCG; First MDI Product Set To Launch Soon; US Market Worth Estimated At $301 Million.
15 Sep 2026 01:05 PM
Aurobindo Pharma: Gains USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 MCG And 80 MCG; First MDI Product Set To Launch Soon; US Market Worth Estimated At $301 Million.
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-IV API Facility Ends with No Issues
11 Sep 2026 05:39 PM
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-IV API Facility Ends with No Issues
Aurobindo Pharma: Company Will Meet Analysts And Investors On September 22 At 9 AM.
11 Sep 2026 04:56 PM
Aurobindo Pharma: Company Will Meet Analysts And Investors On September 22 At 9 AM.
Aurobindo Pharma: Rumors About Block Deal Involving Promoter.
03 Sep 2026 02:50 PM
Aurobindo Pharma: Rumors About Block Deal Involving Promoter.
Aurobindo Pharma: Rumors About Block Deal Involving Promoter. - NDTV Profit
03 Sep 2026 02:50 PM
Aurobindo Pharma: Rumors About Block Deal Involving Promoter. - NDTV Profit
Aurobindo Pharma: Forms New Subsidiary 'Avogent Lifesciences Private Limited' With ₹5 Crore Initial Capital And No Regulatory Approvals Needed.
01 Sep 2026 10:18 AM
Aurobindo Pharma: Forms New Subsidiary 'Avogent Lifesciences Private Limited' With ₹5 Crore Initial Capital And No Regulatory Approvals Needed.
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as subsidiary Lannett launched generic Advair Diskus in the US, targeting a market above US$650mn with limited competition, providing a significant growth opportunity.
01 Sep 2026 08:40 AM
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as subsidiary Lannett launched generic Advair Diskus in the US, targeting a market above US$650mn with limited competition, providing a significant growth opportunity.
Aurobindo Pharma: Lanett Company LLC Introduces Generic Advar Diskus® In The US; It’s The First Product From Their Inhalation Pipeline For Asthma And COPD Treatment.
31 Aug 2026 10:05 AM
Aurobindo Pharma: Lanett Company LLC Introduces Generic Advar Diskus® In The US; It’s The First Product From Their Inhalation Pipeline For Asthma And COPD Treatment.
Aurobindo Pharma: US FDA Finishes Inspection Of Apitoria Pharma's Unit-VI; Three Issues Found.
28 Aug 2026 03:36 PM
Aurobindo Pharma: US FDA Finishes Inspection Of Apitoria Pharma's Unit-VI; Three Issues Found.
Aurobindo Pharma: To Hold Meeting With Analysts And Investors On September 1
25 Aug 2026 06:37 PM
Aurobindo Pharma: To Hold Meeting With Analysts And Investors On September 1
Aurobindo Pharma: Co's Subsidiary, Lannett Company LLC, Faces Four Compliance Issues After US FDA Inspection
24 Aug 2026 09:17 AM
Aurobindo Pharma: Co's Subsidiary, Lannett Company LLC, Faces Four Compliance Issues After US FDA Inspection
Aurobindo Pharma: US FDA Inspection of Auropeptides Ltd Ends With One Finding.
21 Aug 2026 03:36 PM
Aurobindo Pharma: US FDA Inspection of Auropeptides Ltd Ends With One Finding.
Aurobindo Pharma: Eugia Pharma Specialities Gets Warning Letter From US FDA; Current US Supplies Remain Unaffected; This Unit Accounts For About 2% Of Total Revenue.
14 Aug 2026 09:40 AM
Aurobindo Pharma: Eugia Pharma Specialities Gets Warning Letter From US FDA; Current US Supplies Remain Unaffected; This Unit Accounts For About 2% Of Total Revenue.
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as 1QFY27 delivered healthy growth across Europe, RoW and API despite slower US growth, with respiratory launches from Lannett and new plants such as Pen G and China providing growth drivers; FY27 guidance remains double-digit revenue growth with 21%+ margins.
07 Aug 2026 08:55 AM
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as 1QFY27 delivered healthy growth across Europe, RoW and API despite slower US growth, with respiratory launches from Lannett and new plants such as Pen G and China providing growth drivers; FY27 guidance remains double-digit revenue growth with 21%+ margins.
Aurobindo Pharma: BoFA Securities on Aurobindo Pharma Maintains Buy with Target Price of ₹1,800 as 1QFY27 EBITDA margin stood at 21%, with Lannett growth and margin improvement plus profitable contributions from China/Pen G facilities expected to complement base-business momentum and improve long-term growth visibility.
07 Aug 2026 08:56 AM
Aurobindo Pharma: BoFA Securities on Aurobindo Pharma Maintains Buy with Target Price of ₹1,800 as 1QFY27 EBITDA margin stood at 21%, with Lannett growth and margin improvement plus profitable contributions from China/Pen G facilities expected to complement base-business momentum and improve long-term growth visibility.
Aurobindo Pharma: GS on Aurobindo Pharma Maintains Buy with Target Price of ₹1,750 as 1Q revenue/EBITDA grew 16.3%/20% YoY, driven by strong Europe, growth markets and resilient US growth, while EBITDA margin expanded to 21%; FY27 guidance remains double-digit revenue growth with EBITDA margin above 21%.
07 Aug 2026 08:56 AM
Aurobindo Pharma: GS on Aurobindo Pharma Maintains Buy with Target Price of ₹1,750 as 1Q revenue/EBITDA grew 16.3%/20% YoY, driven by strong Europe, growth markets and resilient US growth, while EBITDA margin expanded to 21%; FY27 guidance remains double-digit revenue growth with EBITDA margin above 21%.
Aurobindo Pharma: Bernstein on Aurobindo Pharma Maintains Market Perform with Target Price of ₹1,498 as Q1 delivered steady top-line and earnings growth across geographies, but US ex-Lannett declined 3%, new product approvals slowed, regulatory inspections may limit incremental growth, and Lannett/Advair upside appears largely priced in.
07 Aug 2026 08:56 AM
Aurobindo Pharma: Bernstein on Aurobindo Pharma Maintains Market Perform with Target Price of ₹1,498 as Q1 delivered steady top-line and earnings growth across geographies, but US ex-Lannett declined 3%, new product approvals slowed, regulatory inspections may limit incremental growth, and Lannett/Advair upside appears largely priced in.
Aurobindo Pharma: CLSA on Aurobindo Pharma Maintains Hold with Target Price of ₹1,600 as 1QFY27 was broadly in line with healthy growth across geographies, while FY27 guidance of double-digit revenue growth and 21% margins was reiterated; new product launches and portfolio expansion are expected to drive the full benefit from FY28.
07 Aug 2026 08:56 AM
Aurobindo Pharma: CLSA on Aurobindo Pharma Maintains Hold with Target Price of ₹1,600 as 1QFY27 was broadly in line with healthy growth across geographies, while FY27 guidance of double-digit revenue growth and 21% margins was reiterated; new product launches and portfolio expansion are expected to drive the full benefit from FY28.
